COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.

Nicolas Vuilleumier Marcin KrawczykWiktor SmykFrank LammertAgostino Di Ciaula

Published in: European journal of clinical investigation (2020)

NAFLD can play a role in the outcome of COVID-19 illness due to frequent association with comorbidities. Initial evidences suggest that increased liver fibrosis in NAFLD might affect COVID-19 outcome. In addition, long-term monitoring of post-COVID-19 NAFLD patients is advisable, to document further deterioration of liver damage. Further studies are required in this field.

Keyphrases

coronavirus disease
sars cov
liver fibrosis
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors